Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LENZ Therapeutics (LENZ) EBITDA (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed EBITDA for 4 consecutive years, with -$35.9 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 176.45% to -$35.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$82.1 million through Dec 2025, down 65.56% year-over-year, with the annual reading at -$82.1 million for FY2025, 65.56% down from the prior year.
  • EBITDA for Q4 2025 was -$35.9 million at LENZ Therapeutics, down from -$16.5 million in the prior quarter.
  • The five-year high for EBITDA was -$9.6 million in Q3 2024, with the low at -$35.9 million in Q4 2025.
  • Average EBITDA over 4 years is -$18.9 million, with a median of -$16.5 million recorded in 2025.
  • The sharpest move saw EBITDA skyrocketed 51.19% in 2023, then crashed 176.45% in 2025.
  • Over 4 years, EBITDA stood at -$26.8 million in 2022, then grew by 29.46% to -$18.9 million in 2023, then skyrocketed by 31.22% to -$13.0 million in 2024, then crashed by 176.45% to -$35.9 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$35.9 million, -$16.5 million, and -$15.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.